However, subgroup analysis based on treatment type and comorbidity of diabetes mellitus showed that the effect of improved OS was observed only for patients receiving EGFR-TKIs (HR = 0.73, 95% CI: 0.57–0.94, p = 0.013) (Figure 2B) and those with diabetes mellitus (HR = 0.74, 95% CI: 0.62–0.88, p = 0.001) (Figure 2C). Here, EGFR is linked to diabetes mellitus.